Inhibitory effect of pentosan polysulfate: a potent anti-HIV and antitumor agent on protein serine/threonine and tyrosine kinases (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Inhibitory effect of pentosan polysulfate: a potent anti-HIV and antitumor agent on protein serine/threonine and tyrosine kinases (Meeting abstract).

FASEB J; 6(5):A1851 1992. Unique Identifier : AIDSLINE ICDB/93687627
Chiasson JC; Sekaly RP; Chiasson JL; Srivastava AK; Clinical Res. Inst. of Montreal, Montreal, H2W 1R7 Canada

Abstract: Pentosan polysulfate (PPS), a polyanionic mucopolysaccharide, which has been shown to exert inhibitory effects on human immunodeficiency virus (HIV-I) replication and on tumor growth, inhibited the activities of protein tyrosine kinases (PTK) from lymphocytes (Jurkat cells) and rat lung. In addition, the autophosphorylation of p56lck, a lymphocyte-associated PTK, from Jurkat cells was also inhibited by PPS (100 ug/ml). Furthermore, this mucopolysaccharide also exerted an inhibitory effect on the activities of protein serine/threonine kinases, such as protein kinase C, from human platelets and the catalytic subunit of cAMP-dependent protein kinase from skeletal muscle. However, the activity of phosphorylase kinase was not altered by PPS. The inhibition of rat lung protein tyrosine kinase was rapid and competitive with respect to ATP, with an apparent Ki value of 5-20 ug/ml. These results suggest that the ability of pentosan polysulfate to inhibit various protein serine/threonine and tyrosine kinases may be one of the mechanisms by which this compound exerts its inhibitory effect on HIV-I replication.

Keywords: Animal HIV/*PHYSIOLOGY Lung/ENZYMOLOGY Lymphocytes/ENZYMOLOGY Pentosan Sulfuric Polyester/*PHARMACOLOGY Protein Kinases/METABOLISM Protein-Tyrosine Kinase/METABOLISM Rats Virus Replication/*DRUG EFFECTS ABSTRACT
930430
M9340822

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .